Fulvestrant: observed
53 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT07347600Report a problem
- Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive(HR+) Metastatic Breast Cancer(MBC) .RecruitingNCT06734533Report a problem
- Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast CancerRecruitingNCT06548919Report a problem
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast CancerNot yet recruitingNCT06341283Report a problem
- Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer PatientsRecruitingNCT05680194Report a problem
- A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast CancerCompletedNCT05584644Results postedReport a problem
- Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.CompletedNCT04460911Results postedReport a problem
- Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)CompletedNCT01509625Results postedReport a problem
- A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketCompletedNCT07096024Report a problem
- Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + FulvestrantCompletedNCT07008963Report a problem
- Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)CompletedNCT06525675Report a problem
- A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNCT06311383Report a problem
- Young Patients With Early Breast CancerActive, not recruitingNCT06027541Report a problem
- A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyCompletedNCT05853432Report a problem
- Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.CompletedNCT05789771Report a problem
- Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast CancerCompletedNCT05427617Report a problem
- Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABCStatus unknownNCT05343117Report a problem
- Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-Status unknownNCT05140655Report a problem
- Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up PeriodStatus unknownNCT05135104Report a problem
- Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldCompletedNCT05022342Report a problem
- Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABCStatus unknownNCT05000736Report a problem
- A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingTerminatedNCT04967248Report a problem
- A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNCT04943497Report a problem
- Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf RegionCompletedNCT04916509Report a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownNCT04852081Report a problem
- Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast CancerTerminatedNCT04778982Report a problem
- First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingNCT04767594Report a problem
- Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer PatientsCompletedNCT04681768Report a problem
- Swedish Ibrance Registries Insights (SIRI)CompletedNCT04654208Report a problem
- Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in ChinaStatus unknownNCT04526028Report a problem
- Patterns of Treatment and Outcome of Palbociclib Plus Endocrine TherapyCompletedNCT04524728Report a problem
- TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.CompletedNCT04498481Report a problem
- Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast CancerStatus unknownNCT04289974Report a problem
- Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line ChemotherapyCompletedNCT04258163Report a problem
- Breast Cancer Treatment Based on Organ-like CultureStatus unknownNCT03925233Report a problem
- 500mg Fulvestrant in HR+ MBCCompletedNCT03708432Report a problem
- 500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AICompletedNCT03695341Report a problem
- 500mg Fulvestrant Versus Exemestane in MBCCompletedNCT03575260Report a problem
- Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer PatientsCompletedNCT03541863Report a problem
- Fulvestrant 500mg in Patients With Advanced Breast CancerStatus unknownNCT02909361Report a problem
- Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyCompletedNCT02753686Report a problem
- Faslodex Specific Clinical Experience InvestigationCompletedNCT01501266Report a problem
- Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg TreatmentTerminatedNCT01425294Report a problem
- Fulvestrant in Postmenopausal Patients With Metastatic Breast CancerCompletedNCT01399086Report a problem
- A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerCompletedNCT01171417Report a problem
- Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)CompletedNCT00880711Report a problem
- Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast CancerCompletedNCT00878930Report a problem
- Faslodex Post Marketing SurveillanceCompletedNCT00860561Report a problem
- Faslodex Registry: Fulvestrant in Current Clinical PracticeCompletedNCT00735215Report a problem
- Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in FranceCompletedNCT00681369Report a problem
- Retrospective Brazilian Study of Fulvestrant in Advanced Breast CancerCompletedNCT00660803Report a problem
- Quality Of Life While Receiving FaslodexCompletedNCT00643513Report a problem
- Faslodex Observations During Regular Use by Advanced Mammacarcinoma PatientsTerminatedNCT00241462Report a problem